ArticleBiochemical genetics2026
Tanshinone IIA Inhibits Microglial Activation and Inflammation and Relieves Cerebral Ischemia‒Reperfusion Injury Through TGM2/PANX1.
Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on the molecular mechanisms of tanshinone IIA in the treatment of cardiovascular and cerebrovascular diseases (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Microglial activation and induced inflammation play important roles in cerebral ischemia‒reperfusion injury (CIRI). Tanshinone IIA (Tan IIA) is a natural extract from Chinese herbal medicines that has anti-inflammatory, antioxidant, antiapoptotic and neuroprotective properties and has a protective effect against CIRI. This study aimed to investigate the effects of Tan IIA on microglial activation and inflammation under CIRI and the underlying molecular mechanism. Experimental investigations were conducted using rat and cellular models of CIRI induced by middle cerebral artery occlusion (MCAO) and oxygen‒glucose deprivation/reperfusion (OGD/R), respectively. The neuroprotective effects of Tan IIA on CIRI rats were evaluated through neurological deficit scores, TTC staining, and H&E staining. Immunofluorescence staining and ELISA were used to detect microglial activation and the expression of inflammatory molecules. In this study, treatment with Tan IIA significantly improved neurological deficits, reduced infarct size, and ameliorated pathological damage to the cerebral cortex in CIRI rats. It also decreased the expression of microglial marker Iba-1 and activation marker TSPO, as well as the expression of pro-inflammatory factors TNF-α, IL-1β and IL-6. In terms of molecular mechanisms, the expression of PANX1 and TGM2 is upregulated in this disease, and TGM2 binds to PANX1. The overexpression of PANX1 or TGM2 attenuated the inhibitory effect of Tan IIA on OGD/R-induced microglial activation and inflammation. Overall, Tan IIA inhibits the expression of PANX1 by downregulating TGM2 expression, thereby suppressing microglial activation and inflammation and alleviating CIRI. These findings provide new insights into the role of Tan IIA in the treatment of CIRI.
Indexed as
Identifiers
41351813What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.